CORAL SPRINGS, FL -- (Marketwired) -- 10/22/13 --
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that their Chief Executive Officer, Rik J Deitsch, was interviewed by Chris Castaldo of Wall Street Buy Sell Hold. The interview is an update to the previous one posted in August and provides an outline for the short, mid-term and long-term goals of the company. Castaldo also updated his interview with Jonathan Flicker, the CEO of Nutra Pharma's Nyloxin® Distributor, New Vitality.
"I was excited to have this continuing opportunity to update the public on the Company," commented Rik J Deitsch, CEO of Nutra Pharma Corporation. "We have accomplished a lot of great things since the last interview and still have a lot happening over the next few months. This interview provided a perfect forum for letting our shareholders and the public see our present efforts and future goals," he concluded.
The stated goal at Wall Street Buy Sell Hold (WSBSH) is to identify cutting edge growth companies that offer unique products and services. They then alert individual and professional investors about their discoveries.
"Investing in small and micro-cap stocks can be extremely volatile," stated Chris Castaldo, CEO of Wall Street Buy Sell Hold. "However, with the markets indices at or near all time highs, investors are looking elsewhere to achieve above average gains. I conducted my first interview with the executives from Nutra Pharma and New Vitality in mid-August and I wanted to get an update on their progress since then. I went back to the conference room of New Vitality (Farmingdale, NY), with both Jonathan Flicker and Rik Deitsch for this second interview," he continued. "I continue to believe that we have identified an enormous opportunity and take great pleasure in sharing our findings with the investing public," Castaldo concluded.
In June, Nutra Pharma announced that New Vitality would be test-marketing Nyloxin®, Nutra Pharma's homeopathic treatment for chronic pain. At the end of August, the Company announced that they had delivered the first order of Nyloxin® to New Vitality to begin distribution. For the past 16 years New Vitality has been marketing and selling vitamins, health supplements, and personal care products. Customers learn about their products from advertisements which use celebrities, sport athletes and doctors to promote them on over 2000 radio and television stations nationwide. New Vitality's catalog contains over 150 items which range from energy supplements to fruit and vegetable supplements to colon cleanses and products for men's health.
The interview with Rik Deitsch, CEO of Nutra Pharma, can be viewed at:
The interview with Jonathan Flicker, CEO of New Vitality, can be viewed at:
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com or http://www.nyloxin.com.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The WSBSH interviews should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its present or future financial condition. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Add to DiggBookmark with del.icio.usAdd to Newsvine
Source: Nutra Pharma, Inc.